Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has a beta value of 1.45 and has seen 1,852,279 shares traded in the recent trading session. The company, currently valued at $6.08 Billion, closed the recent trade at $76.03 per share which meant it gained $5.19 on the day or 7.32% during that session. The SRPT stock price is -139.16% off its 52-week high price of $181.83 and 8.51% above the 52-week low of $69.56. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.19 Million shares traded. The 3-month trading volume is 2.19 Million shares.
The consensus among analysts is that Sarepta Therapeutics, Inc. (SRPT) is an Overweight stock at the moment, with a recommendation rating of 2.2. 1 analysts rate the stock as a Sell, while 1 rate it as Overweight. 7 out of 20 have rated it as a Hold, with 11 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$1.78.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) trade information
Sporting 7.32% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, May 03 when the SRPT stock price touched $76.24- or saw a rise of 1.15%. Year-to-date, Sarepta Therapeutics, Inc. shares have moved -55.8%, while the 5-day performance has seen it change 2.82%. Over the past 30 days, the shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have changed -1.11%. Short interest in the company has seen 7.27 Million shares shorted with days to cover at 3.32.
Wall Street analysts have a consensus price target for the stock at $124.31, which means that the shares’ value could jump 63.5% from the levels at last check today. The projected low price target is $72 while the price target rests at a high of $207. In that case, then, we find that the latest price level in today’s session is +172.26% off the targeted high while a plunge would see the stock lose -5.3% from the levels at last check today.
Sarepta Therapeutics, Inc. (SRPT) estimates and forecasts
Figures show that Sarepta Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -49.52% over the past 6 months, with this year growth rate of -14.91%, compared to 8.1% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -673.9% and 10.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be +15.3%.
16 analysts offering their estimates for the company have set an average revenue estimate of $143.33 Million for the current quarter. 16 have an estimated revenue figure of $150.15 Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $119.04 Million and $137.36 Million respectively for this quarter and the next, and analysts expect sales will grow by 20.4% for the current quarter and 9.3% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -6.4% over the past 5 years. Earnings growth for 2021 is a modest +26.8%.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s Major holders
Insiders own 4.8% of the company shares, while shares held by institutions stand at 89.78% with a share float percentage of 94.31%. Investors are also buoyed by the number of investors in a company, with Sarepta Therapeutics, Inc. having a total of 614 institutions that hold shares in the company. The top two institutional holders are Capital Research Global Investors with over 7.74 Million shares worth more than $1.32 Billion. As of December 30, 2020, Capital Research Global Investors held 9.7% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 7.22 Million shares as of December 30, 2020. The firm’s total holdings are worth over $1.23 Billion and represent 9.05% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Growth Fund Of America Inc and Vanguard Total Stock Market Index Fund. As of March 30, 2021, the former fund manager holds about 5.51% shares in the company for having 4396335 shares of worth $327.66 Million while later fund manager owns 2.12 Million shares of worth $360.78 Million as of December 30, 2020, which makes it owner of about 2.65% of company’s outstanding stock.